Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Capricor Therapeutics is mounting a legal fight against a partner over its promising Duchenne therapy, there’s new evidence that scientific creativity calcifies with age, and STAT’s Alex Hogan and Lizzy Lawrence share firsthand accounts from FDA officials who decided the agency was no longer a place they could stay.
Capricor sues partner over Duchenne therapy launch
Capricor Therapeutics is suing its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, arguing the companies botched launch preparations for deramiocel, the biotech’s closely watched Duchenne muscular dystrophy cell therapy. Capricor says the companies also created a pricing structure that could make the treatment financially inaccessible for many patients.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
